1. The Case for Less, Not More, US FDA Regulation

   • John A. Vernon
   • Joseph H. Golec

   Editorial 23 September 2012 Pages: 637 - 640

2. Challenges in Health State Valuation in Paediatric Economic Evaluation

   • Wendy J. Ungar

   Current Opinion 23 September 2012 Pages: 641 - 652

   

3. Cost-of-Illness Studies

   • Allison Larg
   • John R. Moss

   Practical Application 23 September 2012 Pages: 653 - 671

   

4. Using QALYs in Cancer

   • Martina Garau
   • Koonal K. Shah
   • Michael F. Drummond

   Review Article 23 September 2012 Pages: 673 - 685

   

5. US FDA Modernization Act, Section 114

   • Peter J. Neumann
   • Pei-Jung Lin
   • Tom E. Hughes

   Short Communication 23 September 2012 Pages: 687 - 692

   

6. Cost Estimation of Cardiovascular Disease Events in the US

   • Amy K. O’Sullivan
   • Jaime Rubin
   • David Thompson

   Original research Article 23 September 2012 Pages: 693 - 704

   

7. Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive Candidiasis

   • Annette C. Reboli
   • Coleman Rotstein
   • Miriam Tarallo

   Original Research Article 23 September 2012 Pages: 705 - 717

   

8. Estimating the Relationship between Preference-Based Generic Utility Instruments and Disease-Specific Quality-of-Life Measures in Severe Chronic Constipation

   • Mark Parker
   • Alan Haycox
   • Jane Graves

   Original Research Article 23 September 2012 Pages: 719 - 730